Media headlines about Neovasc (NASDAQ:NVCN) (TSE:NVC) have trended somewhat positive on Monday, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neovasc earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media headlines about the medical equipment provider an impact score of 44.6750029464848 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Separately, Zacks Investment Research cut shares of Neovasc from a “hold” rating to a “sell” rating in a report on Wednesday, August 16th.

Shares of Neovasc (NASDAQ:NVCN) traded down 0.58% on Monday, hitting $1.72. 264,928 shares of the company were exchanged. The company has a 50-day moving average price of $1.08 and a 200 day moving average price of $1.38. Neovasc has a 52-week low of $0.45 and a 52-week high of $3.34. The firm’s market cap is $135.73 million.

Neovasc (NASDAQ:NVCN) (TSE:NVC) last posted its quarterly earnings results on Thursday, August 10th. The medical equipment provider reported ($0.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.02). Neovasc had a negative net margin of 68.34% and a negative return on equity of 58.08%. The business had revenue of $1.31 million during the quarter, compared to analysts’ expectations of $1.40 million. Analysts predict that Neovasc will post ($0.34) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Neovasc (NVCN) Share Price” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/25/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-neovasc-nvcn-share-price.html.

About Neovasc

Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.

Insider Buying and Selling by Quarter for Neovasc (NASDAQ:NVCN)

Receive News & Stock Ratings for Neovasc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc. and related stocks with our FREE daily email newsletter.